Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial - 05/10/18
Doi : 10.1016/j.jaci.2018.05.030
Laila Hellkvist, MD a, b, Eric Hjalmarsson, MSc a, Susanna Kumlien Georén, MSc, PhD a, Agneta Karlsson, RN a, b, Karin Lundkvist, MD, PhD a, Ola Winqvist, MD c, Ulla Westin, MD d, Lars Olaf Cardell, MD a, b 
a Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
c Department of Medicine, Unit of Translational Immunology, Karolinska Institutet, Stockholm, Sweden
b Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden
d Laboratory of Clinical and Experimental Allergy Research, Department of Otorhinolaryngology Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 4
P. 1338 - octobre 2018 Retour au numéro
Article précédent
- GM-CSF therapy in human caspase recruitment domain–containing protein 9 deficiency
- Rebecca A. Drummond, Fatema Tuz Zahra, Mukil Natarajan, Muthulekha Swamydas, Amy P. Hsu, L. Joseph Wheat, Christina Gavino, Donald C. Vinh, Steven M. Holland, Constantinos M. Mikelis, Michail S. Lionakis
- IL-33 induces functional CCR7 expression in human mast cells
- Maiko Emi-Sugie, Sumika Toyama, Akio Matsuda, Hirohisa Saito, Kenji Matsumoto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?